<DOC>
	<DOCNO>NCT00247195</DOCNO>
	<brief_summary>This study develop evaluate effectiveness culturally base program aim facilitate entry , retention , successful treatment specialize mental health service Hispanics major depressive disorder .</brief_summary>
	<brief_title>Effectiveness Culturally Based Congruent Care Treating Hispanics With Major Depressive Disorder</brief_title>
	<detailed_description>Major depressive disorder ( MDD ) type depression characterize combination symptom interfere ability work , study , sleep , eat , enjoy activity pleasurable . Studies show individual Hispanic descent underutilize specialized mental health care service ( SMHS ) , despite need . In addition , Hispanic individual associate low rate retention specialize mental health treatment . In particular , dropout rate medication therapy treatment MDD within SMHS two three time higher Hispanics non-Hispanic white . This study develop evaluate effectiveness culturally-based program aim facilitate entry , retention , successful treatment specialize mental health service Hispanics MDD . This open-label study consist four phase . Participants recommend inclusion study upon receive diagnosis MDD base standard health questionnaire complete primary care physician 's office . Phase 1 study entail initial evaluation culturally congruent program care Hispanics MDD ( CCP-MDD ) . Participants place one two focus group , compose 8 10 people . One group include individual refer primary care physician . The group include family member Hispanics MDD . Discussions focus participant ' understanding depression-like illness , treatment expectation condition , perceive barrier SMHS utilization . Information gather focus group use develop second version CCP-MDD . Phase 2 study evaluate revise version CCP-MDD include additional treatment antidepressant medication , weekly interpersonal psychotherapy , combination two . Following treatment , participant take part focus group , involve participant feedback . Based information obtain focus group clinical observation , third version CCP-MDD develop . In Phase 3 , two set primary care office participate . One set assign intervention arm , receive third version CCP-MDD intervention . A second set assign control arm receive usual referral mental health service research site . All participant offer choice treatment : antidepressant medication , weekly interpersonal psychotherapy , combination two . Treatment arm duration , 18 wks . Focus group hold follow treatment order obtain information individual ' satisfaction dissatisfaction care . Based finding , well clinical observation , fourth final version CCP-MDD develop Phase 4 . All treatment last total 18 week . A follow-up session hold Week 30 ass depressive symptom .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>PHASE 1 FOCUS GROUP 1 : Selfidentifies Hispanic Screened positive MDD previous study ( WHPCDP ) , unable participate study due ongoing depression treatment time Spanishspeaking PHASE 1 FOCUS GROUP 2 : Selfidentifies Hispanic Family member patient MDD participate previous study ( WHPCDP ) Spanishspeaking PHASES 13 : PreEngagement Phase Selfidentifies Hispanic Spanishspeaking Positive screen MDD Patient Health Questionnaire ( PHQ ) preliminary diagnosis MDD primary care physician standard medical interview Treatment Phase Meets DSMIV criterion MDD Score least 16 Hamilton Depression Scale ( HAMD17 ) time study entry Willing abstain type specialize mental health service duration treatment ( participant general health care participate folk/spiritual healing practice expect continue study ) Ability tolerate drugfree period ( 2 week medication ; 4 week fluoxetine ) ineffective psychotropic medication ; current medication effective , participant ask discontinue ( zolpidem insomnia also permit medication ) Agrees use effective form contraception duration study Exclusion Criteria PHASE 1 FOCUS GROUP 1 : Comorbid medical psychiatric condition may prevent focus group participation ( e.g. , substance use disorder , psychosis , unstable medical condition ) Active suicidal homicidal ideation may pose danger oneself others PHASE 1 FOCUS GROUP 2 : Comorbid medical psychiatric condition may prevent focus group participation ( e.g. , substance use disorder , psychosis , unstable medical condition ) PHASES 13 : PreEngagement Phase Declines referral primary care physician specialize mental health service Comorbid medical psychiatric condition may prevent safe study participation ( e.g. , substance use disorder , psychosis , unstable medical condition ) Active suicidal homicidal ideation may pose danger oneself others Treatment Phase History schizophrenia , bipolar disorder , schizoaffective disorder , depression psychotic symptom , organic brain syndrome Clinically unstable medical disease , include glaucoma Blood pressure high 150/90 Pregnant breastfeed Current past history seizure disorder ( except febrile seizure childhood ) Meets DSMIV criterion alcohol substance abuse dependence ( except nicotine ) within 6 month prior screen Use monoamine oxidase inhibitor ( MAOIs ) fluoxetine within 4 week prior screen , use selective serotonin reuptake inhibitor ( SSRIs ) , antidepressant , neuroleptic , mood stabilizer , buspirone , benzodiazepine , psychotropic drug , except zolpidem insomnia within 2 week prior screen Currently receive formal psychotherapy mental health provider , whether focus therapy MDD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Major Depression</keyword>
	<keyword>MDD</keyword>
	<keyword>Hispanic</keyword>
	<keyword>Primary Care</keyword>
	<keyword>Cultural Congruence</keyword>
</DOC>